Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHEP-006
- Development stage
- Preclinical
- Lead developer
- Shepherd Therapeutics
01
Overview
SHEP-006 is a preclinical-stage drug candidate being developed by Shepherd Therapeutics for the treatment of various rare cancers, including adenoid cystic carcinoma, adrenocortical carcinoma, carcinoid tumors, cholangiocarcinoma, esophageal cancer, and Ewing's sarcoma. The drug was identified using Shepherd's proprietary DELVE platform, an AI-enabled precision-oncology system that integrates machine learning, bioinformatics, and transcriptome analysis to discover therapies for rare diseases. As of current reports, SHEP-006 is in the IND-enabling phase of development, though its specific molecular target and modality have not been publicly disclosed.
Beyond the preview
Go deeper on SHEP-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHEP-006.